CDC25C and breast carcinoma: Moreover, juglanin was shown to inhibit the proliferation of breast cancer cell proliferation through the differential regulation of cell cycle-associated proteins (i.e., CDC25C, CDK1, CDKN1B, and CHEK2), the activation of the proapoptotic factors BAD, BAX, CASP3, -8 and -9, and, conversely, the suppression of the antiapoptotic protein BCL2 [85].